Digital Health: Company presentation by Hartmut Voss, MCG motion capture at the NOAH Conference Berlin 2019, 13-14 June, STATION.

1. THE PRECISION MOTION ANALYSIS COMPANY
Motion Biomarker in Digital Care
– Making the most of personalized motion data –
NOAH 2019, June 13, Berlin

2.  @NOAHConference
 @noah_conference
 @noah-conference
 @NOAHConference
FOLLOW USONSOCIAL

3. DREAM TEAM MANAGEMENT
Hartmut Voss
Co-CEO
Dievini, Novaliq, Molecular Health
Michael Weber
Co-CEO
Bridges, IIC, bbvl Leipzig
Harald Fricke
CMO Past: Apogenix, Fresenius,
Baxter, SmithKline Beecham
Michael Takla
CTO
VDE, ICW, Lion Bioscience
Not disclosed
CSO –Designated
Big Health Data ML/AI Company
Ralf Stähler
CFO
Ex-CFO of Sana Hospital Chain
2 | © MCG GmbH | Non - Confidential

4. EXECUTIVE SUMMARY
The precision motion analysis and digital care company
2 gold standard wearables. ML/AI BIG DATA analytics. Motion biomarker.
• motion-related diseases
TOP 4 cost-drivers in health care
• D $ 45bn US $220bn
• Aging, poor adherence
unhealthy life style
• costs to raise
• High-quality MedDev wearables
• precision motion ML/AI analytics
• Output: Motion Biomarkers
• Digital guided care concepts
• Track record growing
companies to $200-400mio
• Clinical trials and regulatory
affairs
• Wearable sensors & BIG
Health Data Analytics
• Sports medicine, therapy &
intervention
Solution
Market Need &
Opportunity
Competitive
Advantage
3 | © MCG GmbH |Non-Confidential

5. EXECUTIVE SUMMARY
The precision motion analysis and digital care company
Pharma/Medtech. Healthcare. OHM. Sport.
• Healthcare
knee and hip TEP rehab management post-surgery
Opportunity: $ 1.5bn in D, $ 5bn in US
• Occupational Health Management (OHM)
Backpain management for professional drivers
Opportunity: $ 750mio in D, $ 1.5bn in US
• Pharma and Medtech
Motion Biomarker as endpoints in clinical trials for chronic diseases
Opportunity: $ 150mio in EU and USA
• Sport
Performance improvement and injury prevention in Marathon and Golf
Opportunity: $ 2bn ww
Go-to-Market
4 | © MCG GmbH |Non-Confidential

6. THE MCG SENSOR WEARABLES GENES
2013 2015 2017 20192012 2014 2016 2018
joins MCG
Inception
SPINE v2
Reimburse-
ment
Foundation ofMCG
5 | © MCG GmbH |Non-Confidential
SPINE v1
MedDev
€
• 2000 patients
• 40 Trials
2020
MCG invests
in SenMotion
SenMotion
joins MCG

7. EVOLUTION IN SPINE MOTION DETECTION
Epionics SPINE v2
• Gold standard data outside the lab
• Manufactured by a German MedDev OEM
• Low COGS
• Dynamic, high resolution
• Extension, flexion, rotation angles
• Range of motion and speed
• Long term measure (up to 2 days)
• Instant feed back
costs: > $100.000s costs: $10.000 costs: $500
before therapy 10 days in therapy 2 months after therapy
From: Maier et al, OUP 2015
Camera system in the lab Epionics SPINE v1 Epionics SPINE v2

8. EVOLUTION IN GROUND FORCE DETECTION
costs: $10.000s costs: $500s
SenMotion INSOLE
• Gold standard data outside the lab
• High-precision MedDev wearable
• Comfortable to wear
• Latest technology, low COGS
• Linear detection range: 1-1000N/cm2
• > 1mio steps
• Flexible detection rates 50-500msGround force plate in the lab SenMotion INSOLE in real world
0 500 1000 1500 2000 2500
0
200
400
600
800
1000
1200
SenMotion INSOLE vs Ground Force Plate (Kistler) Long term detection (4h run-stand-run)

9. BUSINESS MODELMCG
Adressing
demand
Driving further
market potential
Focused entry in
4 business
domains
Healthcare
Pharma &
MedTech
OHM
Sports
Profiting from different
market dynamics &
spill-over effects
Effective risk
management through
different revenue streams
Exponentional growth
potential
INDIVIDUAL/PATIENT
PAYER HEALTHCARE
PROFESSIONAL
8 | © MCG GmbH |Non-Confidential

10. INVESTMENT OPPORTUNITY
NEEDCURRENT SEED FUNDING
USE OF PROCEEDS
$ 25 million$ 8.2million
Infrastructure &
Sensors & Al
Developingandhomogenizing
frameworks, wearables &logic
Clinical Studies &
Use Cases
Conducting scientific studies to
validatecommerzialisationofusecases
Market Development &
Penetration
Creatingstrong partnerships acrossall
marketstorolloutservices& products
2-4 INVESTORS (Series A)
for the next 24 months
$ 7.6 million private capital
$ 0.6 million public grants
9 | © MCG GmbH |Non-Confidential

11. GOAL AND EXIT PLAN
We will grow the company until we are strong enough for M&A with a partner,
who can benefit from our health care domain expertise and
take our assets to the next level.
Increase
Company Value
5 year goal
Mid three digit million$
Solid
Revenue
5 year goal
$ 100 million
Health &Cost
Benefit
Leveraging digital technologies
to reduce overall health care costs
& individual disease burden
10 | © MCG GmbH |Non-Confidential